BIOMARKER FOR PREECLAMPSIA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 22, 2016
app pub date -
Jun 27, 2014
filing date -
Jul 1, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention provides a method to diagnose preeclampsia comprising measuring methylation level of at least one gene selected from the group consisting of CPLX2, KIAA1609, MFAP2, CD80, KRT23, PKHD1, STMN2, RAP1A, UBE2G2, KHDC1, SERPINA9, SERPINA5 and PLEKHA2 in a first biological sample from a subject; and diagnosing preeclampsia in said subject based on a higher or lower methylation level in the first biological sample relative to the methylation level in a second biological sample from an individual without preeclampsia or control.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully